Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.

[1]  A. Eggermont,et al.  EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization , 2006, Apoptosis.

[2]  A. Eggermont,et al.  Intratumoural expression of TNF‐R1 and EMAP‐II in relation to response of patients treated with TNF‐based isolated limb perfusion , 2006, International Journal of Cancer.

[3]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[4]  Sunghoon Kim,et al.  Structural separation of different extracellular activities in aminoacyl-tRNA synthetase-interacting multi-functional protein, p43/AIMP1. , 2006, Biochemical and biophysical research communications.

[5]  S. Corbett,et al.  Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. , 2005, Experimental cell research.

[6]  Sunghoon Kim,et al.  Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. , 2005, Trends in biochemical sciences.

[7]  S. Libutti,et al.  Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. , 2005, Cytokine.

[8]  H. Schluesener,et al.  Expression of P2X4 receptor by lesional activated microglia during formalin-induced inflammatory pain , 2005, Journal of Neuroimmunology.

[9]  Sun-Young Chang,et al.  Heparan Sulfate Regulates the Antiangiogenic Activity of Endothelial Monocyte-Activating Polypeptide-II at Acidic pH , 2005, Molecular Pharmacology.

[10]  Sunghoon Kim,et al.  The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. , 2005, The American journal of pathology.

[11]  V. Hombach,et al.  Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  A. Eggermont,et al.  One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases , 2004, Annals of surgery.

[13]  Meijing Wang,et al.  Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  Sunghoon Kim,et al.  Aminoacyl-tRNA synthetase complexes: beyond translation , 2004, Journal of Cell Science.

[15]  M. Schwarz,et al.  In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. , 2004, The Journal of surgical research.

[16]  A. Eggermont,et al.  Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy. , 2004, Anticancer research.

[17]  P. Symonds,et al.  Endothelial monocyte‐activating polypeptide‐II (EMAP‐II): a novel inducer of lymphocyte apoptosis , 2004, Journal of leukocyte biology.

[18]  P. Schimmel,et al.  Relationship of two human tRNA synthetases used in cell signaling. , 2004, Trends in biochemical sciences.

[19]  F. Neumann,et al.  Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. , 2004, Molecular pharmacology.

[20]  P. Symonds,et al.  Colorectal Cancer Cells Induce Lymphocyte Apoptosis by an Endothelial Monocyte-Activating Polypeptide-II-Dependent Mechanism 1 , 2004, The Journal of Immunology.

[21]  J. Schwab,et al.  Spinal cord injury induces lesional expression of the proinflammatory and antiangiogenic cytokine EMAP II. , 2003, Journal of neurotrauma.

[22]  S. Libutti,et al.  Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. , 2003, Cancer research.

[23]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[24]  D. Ruiter,et al.  EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. , 2003, Investigative ophthalmology & visual science.

[25]  J. Richt,et al.  Accumulation of the proinflammatory cytokine endothelial-monocyte-activating polypeptide II in ramified microglial cells in brains of Borna virus infected Lewis rats , 2003, Neuroscience Letters.

[26]  J. Schwab,et al.  Lesional expression of a proinflammatory and antiangiogenic cytokine EMAP II confined to endothelium and microglia/macrophages during secondary damage following experimental traumatic brain injury , 2003, Journal of Neuroimmunology.

[27]  J. Schaper,et al.  Regulation of EMAP II by hypoxia. , 2003, The American journal of pathology.

[28]  P. Schimmel,et al.  Mutational switching of a yeast tRNA synthetase into a mammalian-like synthetase cytokine. , 2002, Biochemistry.

[29]  Sunghoon Kim,et al.  Dose-dependent Biphasic Activity of tRNA Synthetase-associating Factor, p43, in Angiogenesis* , 2002, The Journal of Biological Chemistry.

[30]  Sunghoon Kim,et al.  Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. , 2002, Cytokine.

[31]  S. Libutti,et al.  Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. , 2002 .

[32]  F. Michetti,et al.  Expression of EMAP-II by Activated Monocytes/Microglial Cells in Different Regions of the Rat Hippocampus after Trimethyltin-Induced Brain Damage , 2002, Experimental Neurology.

[33]  H. Jabbour,et al.  Expression and Localization of Endothelial Monocyte-Activating Polypeptide II in the Human Endometrium across the Menstrual Cycle: Regulation of Expression by Prostaglandin E2 , 2002 .

[34]  M. Schwarz,et al.  Pro-EMAP II is not primarily cleaved by caspase-3 and -7. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[35]  Sunghoon Kim,et al.  Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. , 2002, The Journal of biological chemistry.

[36]  B. Rouse,et al.  Control of stromal keratitis by inhibition of neovascularization. , 2001, The American journal of pathology.

[37]  P. Vandenabeele,et al.  The EMAPII Cytokine Is Released from the Mammalian Multisynthetase Complex after Cleavage of Its p43/proEMAPII Component* , 2001, The Journal of Biological Chemistry.

[38]  Sunghoon Kim,et al.  A Cofactor of tRNA Synthetase, p43, Is Secreted to Up-regulate Proinflammatory Genes* , 2001, The Journal of Biological Chemistry.

[39]  S. Hayashi,et al.  Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). , 2000, Anticancer research.

[40]  J. Shin,et al.  A novel anti-tumor cytokine contains an RNA binding motif present in aminoacyl-tRNA synthetases. , 2000, The Journal of biological chemistry.

[41]  S. Libutti,et al.  Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. , 2000, Journal of immunotherapy.

[42]  C J Gomer,et al.  Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. , 2000, Cancer research.

[43]  S. Libutti,et al.  Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). , 2000, Cytokine.

[44]  E. Kohn,et al.  Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. , 2000, Microvascular research.

[45]  J. Warrington,et al.  The Cytokine Portion of p43 Occupies a Central Position within the Eukaryotic Multisynthetase Complex* , 2000, The Journal of Biological Chemistry.

[46]  J. Carmichael,et al.  Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. , 2000, Cancer research.

[47]  David Warburton,et al.  The molecular basis of lung morphogenesis , 2000, Mechanisms of Development.

[48]  P. Vandenabeele,et al.  The endothelial monocyte‐activating polypeptide II (EMAP II) is a substrate for caspase‐7 , 2000, FEBS letters.

[49]  J. Gottsch,et al.  Apoptosis induced by a corneal-endothelium-derived cytokine. , 1999, Investigative ophthalmology & visual science.

[50]  S. Libutti,et al.  Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. , 1999, Cancer research.

[51]  P. Vandenabeele,et al.  Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. , 1999, The Journal of clinical investigation.

[52]  P. Schimmel,et al.  Highly Differentiated Motifs Responsible for Two Cytokine Activities of a Split Human tRNA Synthetase* , 1999, The Journal of Biological Chemistry.

[53]  Jun Li,et al.  Endothelial-Monocyte Activating Polypeptide Ii, a Novel Antitumor Cytokine That Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells , 1999, The Journal of experimental medicine.

[54]  P. Schimmel,et al.  Structure‐specific tRNA‐binding protein from the extreme thermophile Aquifex aeolicus , 1999, The EMBO journal.

[55]  M. Tan,et al.  The micronuclear gene encoding a putative aminoacyl-tRNA synthetase cofactor of the ciliate Euplotes octocarinatus is interrupted by two sequences that are removed during macronuclear development. , 1999, Gene.

[56]  P. Baker,et al.  Endothelial Monocyte-Activating Polypeptide-2 Is Increased in Pregnancy but Is Not Further Increased in Preeclampsia , 1999, The Journal of the Society for Gynecologic Investigation: JSGI.

[57]  P. Schimmel,et al.  Two distinct cytokines released from a human aminoacyl-tRNA synthetase. , 1999, Science.

[58]  D. Warburton,et al.  EMAP II: a modulator of neovascularization in the developing lung. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[59]  M. Siatecka,et al.  Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. , 1999, Journal of molecular biology.

[60]  S. Wolin,et al.  The trials and travels of tRNA. , 1999, Genes & development.

[61]  S. Libutti,et al.  In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). , 1999, Cancer research.

[62]  W. Risau,et al.  Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. Lassmann,et al.  Coronavirus Infection and Demyelination , 1998 .

[64]  E. Hurt,et al.  A conserved domain within Arc1p delivers tRNA to aminoacyl-tRNA synthetases. , 1998, Molecular cell.

[65]  M. Mirande,et al.  The p43 Component of the Mammalian Multi-synthetase Complex Is Likely To Be the Precursor of the Endothelial Monocyte-activating Polypeptide II Cytokine* , 1997, The Journal of Biological Chemistry.

[66]  H. Schluesener,et al.  Localization of endothelial‐monocyte‐activating polypeptide II (EMAP II), a novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: Expression by monocytes and activated microglial cells , 1997, Glia.

[67]  M. Mirande,et al.  The p18 component of the multisynthetase complex shares a protein motif with the β and γ subunits of eukaryotic elongation factor 1 , 1996 .

[68]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Libutti,et al.  A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. , 1996, The Journal of surgical research.

[70]  D. Yang.  Mammalian aminoacyl-tRNA synthetases. , 1996, Current topics in cellular regulation.

[71]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[72]  S. Libutti,et al.  Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. , 1994, The Journal of biological chemistry.

[73]  W. Kisiel,et al.  A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. , 1994, The Journal of biological chemistry.

[74]  P. Familletti,et al.  Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. , 1992, The Journal of biological chemistry.

[75]  S D Prionas,et al.  Dual role of tumor necrosis factor-alpha in angiogenesis. , 1992, The American journal of pathology.

[76]  M. Mirande.  Aminoacyl-tRNA synthetase family from prokaryotes and eukaryotes: structural domains and their implications. , 1991, Progress in nucleic acid research and molecular biology.

[77]  D. Connolly,et al.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.

[78]  P. Familletti,et al.  A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. , 1990, The Journal of biological chemistry.

[79]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[80]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[81]  H. Gerlach,et al.  Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas , 1988, Journal of Experimental Medicine.

[82]  A. Asher,et al.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.

[83]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[84]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[85]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[86]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[87]  J. Tavernier,et al.  Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. , 1985, European journal of biochemistry.

[88]  T. Shirai,et al.  Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor , 1985, Nature.

[89]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[90]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.